Definitive Contract 75N93019C00029
Award Date
9/16/19
Potential Completion Date
7/1/24
Potential Value
$2.9M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
KJ Biosciences LLC
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
College Station, TX 77840, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This is a $449,620.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to KJ Biosciences LLC, a minority-owned, for-profit limited liability company located in College Station, Texas. The contract is for the development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A, with a period of performance from July...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The $2,338,680.13 definitive contract is for the Phase II development of a prophylactic onchocerciasis (river blindness) vaccine under the SBIR program. The contract is a cost plus fixed fee arrangement with a completion date of May 15, 2024. PAI Life Sciences is collaborating with Thomas...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awarded a $298,596 definitive contract to Sanaria Inc. of Potomac, MD for Research Type Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from August 30, 2022 through April 1, 2024. The place of performance is Potomac, MD and the contract has a total small business set aside...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $33,273,522 cost-plus-fixed-fee definitive contract to Anivive Lifesciences Inc., a self-certified small disadvantaged business, to develop vaccine candidates for biodefense and emerging infectious diseases. This contract, awarded on June 7, 2024, is part of NIAID's Broad Agency Announcement (BAA) research program and has a completion date of June 1, 2026. The contract...
This $596,519 fixed-price federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Ampersand Biosciences LLC, a woman-owned small business. The contract is for the development of reagents to support immunologic analysis of non-mammalian and underrepresented mammalian models, such as ferrets and mice, under SBIR Topic 107. This aligns with NIAID's mission to conduct and support research to...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government. The contract, with a ceiling value of $299,943.00, has been awarded to Lifetime Omics, Inc., a minority-owned, woman-owned, and small disadvantaged business. The contract is for research related to SBIR Topic 123, with a completion date of November 30, 2024. The contract is a definitive contract with a firm...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
This is a $299,208 firm fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to John Snow Labs Inc., a self-certified small disadvantaged business. The contract is for SBIR Topic 135, with a period of performance through September 4, 2025. The contract does not have a set-aside designation. As an SBIR (Small Business Innovation Research) contract, it is part of a larger SBIR program managed by NIAID to fund research and...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...